This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ACADIA Pharmaceuticals Reports Promising Effects Of Pimavanserin In Preclinical Model Of Alzheimer’s Disease Psychosis

ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical company focused on innovative treatments that address unmet medical needs in neurological and related central nervous system disorders, today announced results of preclinical studies, which suggest that pimavanserin, ACADIA’s proprietary product candidate currently in Phase III development for Parkinson’s disease psychosis, also may have therapeutic benefits in the treatment of Alzheimer’s disease psychosis (ADP). Results of these studies were published in the scientific journal, Behavioural Pharmacology (Price et al., “Pimavanserin, a 5-HT 2A Receptor Inverse Agonist, Reverses Psychosis-like Behaviors in a Rodent Model of Alzheimer’s Disease,” July 2012 e-pub).

ACADIA scientists reported results of experiments using mice that had received intracerebroventricular (ICV) infusion of an amyloid β peptide fragment and developed Alzheimer’s disease-like pathology. These animals developed psychosis-like behaviors with enhanced responses to the psychostimulants DOI and amphetamine as well as disrupted prepulse inhibition. Treatment with pimavanserin prevented DOI-induced responses, reversed the augmented responses to amphetamine, and normalized prepulse inhibition in animals with amyloid pathology. These findings suggest that 5-HT 2A antagonists/inverse agonists, such as pimavanserin, may be effective in the treatment of patients with ADP.

“ADP represents a major unmet medical need with no proven safe and effective therapy,” said Uli Hacksell, Ph.D., ACADIA’s Chief Executive Officer. “Physicians often resort to off-label use of antipsychotic medications in patients with ADP despite their association with increased mortality and potential worsening of cognitive disturbances. These new findings suggest that pimavanserin may be ideally suited to address the need for a new ADP treatment that is safe, effective and well tolerated.”

About Alzheimer’s Disease Psychosis

Alzheimer’s disease is a neurodegenerative disorder characterized by progressive deterioration in cognitive functioning, memory abnormalities, and a host of behavioral and neuropsychiatric symptoms. According to the Alzheimer’s Association, 5.4 million people in the United States are living with Alzheimer’s disease. An estimated 25 to 50 percent of Alzheimer’s patients may develop Alzheimer’s disease psychosis (ADP), which commonly consists of disturbing visual hallucinations and delusions. ADP is associated with greater cognitive impairment, more rapid disease progression, lower quality of life, greater caregiver burden, and earlier institutionalization. Currently, there is no therapy approved to treat ADP in the United States.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,070.40 +46.34 0.26%
S&P 500 2,114.49 +6.20 0.29%
NASDAQ 5,016.9290 +11.5380 0.23%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs